Arm Holdings (NASDAQ: ARM) often seems misunderstood by the stock market. The company has a unique business model as it licenses its CPU designs and then earns royalty revenue when the products with those designs are sold. That misunderstanding has manifested itself in the response to its earnings reports. For instance, the stock initially fell […]
Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions. Neither stock looks overpriced, with valuations below the sector average. 10 stocks we like better than Halozyme Therapeutics › The biotech sector returned to health in 2025 after years of […]